These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25701120)

  • 1. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
    Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
    Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
    Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers.
    Ahmad DA; Negm OH; Alabdullah ML; Mirza S; Hamed MR; Band V; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Oct; 159(3):457-67. PubMed ID: 27592113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
    Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
    Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
    Sengupta S; Schiff R; Katzenellenbogen BS
    Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
    Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
    Dey N; De P; Leyland-Jones B
    Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
    Xu JH; Wang Y; Xu D
    Cancer Biomark; 2019; 25(2):193-201. PubMed ID: 31104012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
    Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
    PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
    Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
    Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
    Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
    Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.
    Jerjees DA; Alabdullah M; Alkaabi M; Abduljabbar R; Muftah A; Nolan C; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Aug; 147(1):25-37. PubMed ID: 25085753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer.
    Habashy HO; Rakha EA; Aleskandarany M; Ahmed MA; Green AR; Ellis IO; Powe DG
    Breast Cancer Res Treat; 2011 Aug; 129(1):11-21. PubMed ID: 21336599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.